IGF-1 LR3 is a modified variant of Insulin-like Growth Factor 1 (IGF-1) designed with an extended half-life and reduced binding to IGF-binding proteins, leading to increased free IGF-1 activity. While IGF-1 signaling is essential for growth and tissue repair, chronically elevated levels are generally associated with increased risk of certain cancers and may negatively impact longevity pathways by suppressing cellular housekeeping mechanisms.
Verdict
Avoid for healthspan; significant risks outweigh unproven benefits.
HEALTHSPAN IMPACT
Negligible
RISK LEVEL
High
EVIDENCE GRADE
C
MONTHLY COST
$50 - $200
Protocol
- Typically administered via subcutaneous injection in doses ranging from 20-100 mcg per day, often in cycles lasting several weeks.
- No established clinical protocol exists for healthspan application due to lack of regulatory approval and evidence.
Flags
- Potentially increases risk of certain cancers, particularly with chronic use.
- May induce hypoglycemia, requiring careful monitoring.
- Risk of localized injection site reactions and infection.
- Long-term systemic effects on organ growth are not well characterized.
- Lack of regulatory oversight means product purity and dosage are often unreliable.